Lubinski, J, Kotsopoulos, J, Moller, P, Pal, T, Eisen, A, Peck, L, Karlan, BY, Aeilts, A, Eng, C, Bordeleau, L, Foulkes, WD, Tung, N, Couch, FJ, Fruscio, R, Cajal, T, Singer, CF, Neuhausen, SL, Zakalik, D, Cybulski, C, Gronwald, J, Huzarski, T, Stempa, K, Dungan, J, Cullinane, C, Olopade, OI, Metcalfe, K, Sun, P, Narod, SA. MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. 2024; DOI:10.1001/jamaoncol.2023.6944. PMID:38421676. IF:20.100(Q1/1D).

Motzer, RJ, Porta, C, Eto, M, Powles, T, Gruenwald, V, Hutson, TE, Alekseev, B, Rha, SY, Merchan, J, Goh, JC, Lalani, AKA, De Giorgi, U, Melichar, B, Hong, SH, Gurney, H, Mendez-Vidal, MJ, Kopyltsov, E, Tjulandin, S, Gordoa, TA, Kozlov, V, Alyasova, A, Winquist, E, Maroto, P, Kim, M, Peer, A, Procopio, G, Takagi, T, Wong, SR, Bedke, J, Schmidinger, M, Rodriguez-Lopez, K, Burgents, J, He, CX, Okpara, CE, Mckenzie, J, Choueiri, TK. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(11)DOI:10.1200/JCO.23.01569. PMID:38227898. IF:41.900(Q1/1D).

Rofes, P, Dueñas, N, del Valle, J, Navarro, M, Balmaña, J, Ramón y Cajal, T, Tuset, N, Castillo, C, González, S, Brunet, J, Capellá, G, Lázaro, C, Pineda, M. Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation. Cancer Medicine. 2024; 13(7)DOI:10.1002/cam4.7041. PMID:38558366. IF:3.100(Q2/5D).

Rueda, AG, Taus, A, Alvarez, RA, Bernabé-Caro, R, Chara, L, López-Brea, M, Vilà, L, González, MAS, Aldagalán, ADD, Herrera, BE, Castro, RL, Cabellos, RA, Doménech, M, Falagan, S, Vega, AM, Aguado, C, Barba, A, Ureña, MTD, Isla, D, Hernández, LB, Pérez, JLF, Juan-Vidal, O, Massuti, B, Mielgo-Rubio, X, Ortega, AL, Catot, S, Dómine, M, Escoín-Pérez, C, Navalón, FG, Gil-Bazo, I, Muñoz, S, Rodríguez-Abreu, D, Roldán, RMV, Curbera, GA, León-Mateos, L, Padilla, A, Lario, AP, Sánchez-Torres, JM, Garrido, P. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clinical & Translational Oncology. 2024; 26(9)DOI:10.1007/s12094-024-03404-9. PMID:38512450. IF:2.500(Q3/6D).